1. Market Research
  2. > MethylGene Inc. – Product Pipeline Review – 2013

MethylGene Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 86 pages

MethylGene Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “MethylGene Inc. - Product Pipeline Review - 2013” provides data on the MethylGene Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MethylGene Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from MethylGene Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MethylGene Inc. - Brief MethylGene Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MethylGene Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MethylGene Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MethylGene Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MethylGene Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MethylGene Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MethylGene Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MethylGene Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MethylGene Inc. and identify potential opportunities in those areas.

Table Of Contents

MethylGene Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
MethylGene Inc. Snapshot 6
MethylGene Inc. Overview 6
Key Information 6
Key Facts 6
MethylGene Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
MethylGene Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
MethylGene Inc. - Pipeline Products Glance 13
MethylGene Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
MethylGene Inc. - Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
MethylGene Inc. - Drug Profiles 16
Kinase Inhibitors 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
MG-516 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
MG-96077 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
MGCD-265 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
MGCD-265 + [erlotinib hydrochloride] 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
MGCD-290 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
MGCD-290 + [fluconazole] 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
mocetinostat 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MethylGene Inc. - Pipeline Analysis 31
MethylGene Inc. - Pipeline Products by Therapeutic Class 31
MethylGene Inc. - Pipeline Products by Route of Administration 32
MethylGene Inc. - Pipeline Products By Mechanism of Action 33
MethylGene Inc. - Recent Pipeline Updates 35
MethylGene Inc. - Dormant Projects 42
MethylGene Inc. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
MG-98 43
MG-98 + [interferon alfa-2b] 43
MethylGene Inc. - Company Statement 44
MethylGene Inc. - Locations And Subsidiaries 49
Head Office 49
Other Locations and Subsidiaries 49
MethylGene Inc., Recent Developments 50
MethylGene Inc.- Press Release 50
Apr 08, 2013: MethylGene Presents Preclinical Data On MG516 At AACR Annual Meeting 50
Mar 18, 2013: MethylGene Reports Results Of Phase II Trial Of MGCD290 50
Dec 06, 2010: Methylgene Reports Favorable Final Phase II Clinical Data Of Mocetinostat In Hodgkin Lymphoma 51
Nov 29, 2010: Methylgene To Present Final Phase II Clinical Data Of Mocetinostat At ASH Annual Meeting 52
Nov 18, 2010: Methylgene Presents Encouraging Clinical Data From CD265 In Solid Tumor Cancers At 22nd EORTC-NCI-AACR Annual Meeting 52
Nov 18, 2010: Methylgene Presents Encouraging Clinical Data On CD265 With Erlotinib In Solid Tumor Cancers At EORTC-NCI-AACR Annual Meeting 53
Sep 28, 2010: Methylgene Wins Two US Patents For MGCD265 54
Sep 13, 2010: Methylgene Presents Phase I Data Of MGCD290 At 50th Annual ICAAC Meeting 54
Sep 13, 2010: Methylgene Presents Phase I Data Of MGCD290 In Combination With Fluconazole At 50th Annual ICAAC Meeting 55
Jun 07, 2010: Methylgene Presents Encouraging Clinical Data Of MGCD265 At ASCO 2010 Annual Meeting 56
Jun 07, 2010: Methylgene Presents Encouraging Preclinical Data For MGCD265 At ASCO 2010 Annual Meeting 58
Jun 07, 2010: Methylgene Presents Phase II Clinical Data For Mocetinostat At ASCO 2010 Annual Meeting 59
Apr 20, 2010: Methylgene Presents Preclinical Data For MGCD265 At AACR Annual Meeting 60
Financial Deals Landscape 62
MethylGene Inc., Deals Summary 62
MethylGene Inc., Pharmaceuticals and Healthcare, Deal Details 64
Partnerships 64
MethylGene Extends Its Research Collaboration With Otsuka Pharma 64
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene 66
Methylgene Enters Into Research Agreement With Pharmion 68
Licensing Agreements 70
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 70
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 71
Equity Offering 72
MethylGene Completes Private Placement Of Units For $26 Million 72
MethylGene Completes Second Tranche Of Private Placement Of Units For $1 Million 75
MethylGene Announces Private Placement Of $15 Million 78
MethylGene Completes Private Placement Of $9.1 Million 79
MethylGene Completes Bought Deal Offering Of $17 Million 81
Debt Offering 83
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86



List of Tables

MethylGene Inc., Key Information 6
MethylGene Inc., Key Facts 6
MethylGene Inc. - Pipeline by Indication, 2013 9
MethylGene Inc. - Pipeline by Stage of Development, 2013 10
MethylGene Inc. - Monotherapy Products in Pipeline, 2013 11
MethylGene Inc. - Combination Treatment Modalities in Pipeline, 2013 12
MethylGene Inc. - Phase II, 2013 13
MethylGene Inc. - Phase I, 2013 14
MethylGene Inc. - Pre-Clinical, 2013 15
MethylGene Inc. - Pipeline By Therapeutic Class, 2013 31
MethylGene Inc. - Pipeline By Route of Administration, 2013 32
MethylGene Inc. - Pipeline Products By Mechanism of Action, 2013 34
MethylGene Inc. - Recent Pipeline Updates, 2013 35
MethylGene Inc. - Dormant Developmental Projects,2013 42
MethylGene Inc. - Discontinued Pipeline Products, 2013 43
MethylGene Inc., Subsidiaries 49
MethylGene Inc., Deals Summary 62
MethylGene Extends Its Research Collaboration With Otsuka Pharma 64
MethylGene Enters Into Royalty Stream And Milestone Arrangement With Celgene 66
Methylgene Enters Into Research Agreement With Pharmion 68
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 70
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 71
MethylGene Completes Private Placement Of Units For $26 Million 72
MethylGene Completes Second Tranche Of Private Placement Of Units For $1 Million 75
MethylGene Announces Private Placement Of $15 Million 78
MethylGene Completes Private Placement Of $9.1 Million 79
MethylGene Completes Bought Deal Offering Of $17 Million 81
MethylGene Completes Private Placement Of Senior Unsecured Debentures For $0.39 Million 83



List of Figures

MethylGene Inc. - Pipeline by Indication, 2013 8
MethylGene Inc. - Pipeline by Stage of Development, 2013 10
MethylGene Inc. - Monotherapy Products in Pipeline, 2013 11
MethylGene Inc. - Combination Treatment Modalities in Pipeline, 2013 12
MethylGene Inc. - Pipeline By Therapeutic Class, 2013 31
MethylGene Inc. - Pipeline Products By Mechanism of Action, 2013 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.